SIONNA THERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
SIONNA THERAPEUTICS, INC. (SION) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $981.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- SIONNA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $492.00K, a 0.41% increase year-over-year.
- SIONNA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $489.00K, a 0.41% decline year-over-year.
- SIONNA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $491.00K, a 0.20% increase year-over-year.
- SIONNA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $490.00K, a 0.00% change year-over-year.
- SIONNA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.96M, a 0.00% change from fiscal 2024.
- SIONNA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.96M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $492.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $981.00K 10-Q · filed 2026-08-06 | $1.47M derived: sum of 3 quarters · filed 2026-08-06 | $1.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $489.00K 10-Q · filed 2026-05-12 | $980.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.47M derived: sum of 3 quarters · filed 2026-05-12 | $1.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $491.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $981.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.47M derived: sum of 3 quarters · filed 2026-08-06 | $1.96M 10-K · filed 2026-03-02 |
| 2025-09-30 | $490.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $980.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.47M 10-Q · filed 2025-11-05 | $1.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $490.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $981.00K 10-Q · filed 2026-08-06 | $1.47M derived: sum of 3 quarters · filed 2026-08-06 | $1.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $491.00K 10-Q · filed 2026-05-12 | $981.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.47M derived: sum of 3 quarters · filed 2026-05-12 | $1.96M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $490.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $980.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.47M derived: sum of 3 quarters · filed 2026-03-02 | $1.96M 10-K · filed 2026-03-02 |
| 2024-09-30 | $490.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $980.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.47M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $490.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $982.00K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $492.00K 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |